US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of MM120 orally disintegrating tablets (MM120 ODT) for the treatment of ...
MindMed stock is surging today following a recent report from a Minnesota-based task force that urged the decriminalization of psychedelic mushrooms. The clinical-stage biotech specialist is focused ...
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel ...
In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120 as a treatment for anxiety.
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
MindMed Posters are available on MindMed’s Company website. About MindMed MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders.
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Mind Medicine has commenced its ...
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
NEW YORK, December 11, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company ...
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback